CRL (CRL) Price Target
Track Wall Street analyst price targets and coverage changes.
Consensus Price Target
$178.00
▲
14.4%
Upside
based on current price $155.55
High Target
$205.00
Median Target
$178.00
Low Target
$151.00
Analyst Coverage
Last Month
0
$0.00
Last Quarter
0
$0.00
Last Year
9
$236.67
Individual Price Targets
Latest Analyst Coverage
| Date | Analyst | Firm | Target | Price When Posted | Upside | News |
|---|---|---|---|---|---|---|
| Oct 15, 2024 | Luke Sergott | Barclays | $205.00 | $193.14 | 6.1% | Charles River price target lowered to $205 from $210 at Barclays |
| Oct 14, 2024 | Jamie Clark | Redburn Partners | $151.00 | $192.97 | -21.7% | Charles River initiated with a Sell at Redburn Atlantic |
| Sep 17, 2024 | Ann Hynes | Mizuho Securities | $210.00 | $206.44 | 1.7% | Mizuho Reiterates Neutral Rating on Charles River Labs (CRL) |
| Aug 08, 2024 | Justin Bowers | Deutsche Bank | $240.00 | $200.34 | 19.8% | Charles River price target lowered to $240 from $300 at Deutsche Bank |
| Jul 10, 2024 | Eric Coldwell | Robert W. Baird | $239.00 | $201.85 | 18.4% | Charles River price target lowered to $239 from $271 at Baird |
| Jun 28, 2024 | Luke Sergott | Barclays | $230.00 | $207.35 | 10.9% | Barclays Starts Charles River Labs (CRL) at Equalweight |
| Jun 06, 2024 | Matthew Sykes | Goldman Sachs | $290.00 | $216.12 | 34.2% | Goldman Sachs Starts Charles River Labs (CRL) at Buy |
| May 09, 2024 | Elizabeth Anderson | Evercore ISI | $265.00 | $230.09 | 15.2% | Charles River Labs (CRL) PT Lowered to $265 at Evercore ISI |
| Apr 01, 2024 | Elizabeth Anderson | Evercore ISI | $300.00 | $270.95 | 10.7% | Charles River Labs (CRL) PT Raised to $300 at Evercore ISI |
Related Metrics
Explore detailed financial metrics and analysis for CRL.